Showing 7311-7320 of 9753 results for "".
- Nutrafol Rolls Out New Products Aimed at Balancing the Scalp Microbiomehttps://practicaldermatology.com/news/nutrafol-rolls-out-new-products-aimed-at-balancing-the-scalp-microbiome/2461225/
- Zocdoc Highlights The Year in Skincarehttps://practicaldermatology.com/news/zocdoc-highlights-the-year-in-skincare/2461206/Dermatology consultation and follow-up appointments increased by 16 percent from January-April 2021 to January-April 2022, and while many American patients and dermatologists turned to telehealth as a
- CeraVe Shares Real Stories of Four Nurses with the Return of Heroes Behind the Maskshttps://practicaldermatology.com/news/cerave-shares-real-stories-of-four-nurses-with-the-return-heroes-behind-the-masks/2461186/In honor of National Nurses Week, CeraVe reinforces its commitment to the nursing community with the premiere of
- RedDress Ships ActiGraft to Ukraine to Treat Civilian Casualtieshttps://practicaldermatology.com/news/reddress-ships-actigraft-to-ukraine-to-treat-civilian-casualties/2461133/
- Update: Skin Reactions to COVID-19 and Its Vaccineshttps://practicaldermatology.com/news/update-skin-reactions-to-covid-19-and-its-vaccines/2461125/
- Juvederm Volbella XC Scores FDA Nod for Undereye Hollowshttps://practicaldermatology.com/news/juvederm-volbella-xc-scores-fda-nod-for-undereye-hollows/2461071/The US Food and Drug Administration has given its nod to Allergan Aesthetics, Juvederm Volbella XC for improvement of infraorbital hollows in adults over the age of 21. Per FDA requirement for this new indication, Allergan Aesthetics is providing a product training
- Lubriderm Launches Skin Scholarship with the National Hispanic Health Foundationhttps://practicaldermatology.com/news/lubriderm-launches-skin-scholarship-with-the-national-hispanic-health-foundation/2461030/Lubriderm is partnering with the
- Tremfya Five-Year Data Show No New Safety Signalshttps://practicaldermatology.com/news/tremfya-five-year-data-show-no-new-safety-signs/2461016/New data published in the
- Rinvoq Scores FDA Nod for Active Psoriatic Arthritishttps://practicaldermatology.com/news/rinvoq-scores-us-fda-nod-for-active-psoriatic-arthritis/2461012/The U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. "The efficacy
- New Collaboration Seeks to Establish Nocturnal Scratch as a Digital Endpoint for ADhttps://practicaldermatology.com/news/new-collaboration-seeks-to-establish-nocturnal-scratch-as-a-digital-endpoint-for-ad/2460986/Advancing the use of digital endpoints in medical research and care, a new collaboration between